Related Experiment Video

Updated: Sep 11, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Emerging pharmacological strategies in lipoprotein(a) reduction

Taha Mansoor1, Mahmoud Ismayl2, Sachin Parikh3

  • 1Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA.

Proceedings (Baylor University. Medical Center)
|August 18, 2025
PubMed

Insights

Elevated Lipoprotein(a) (Lp(a)) is a risk for cardiovascular disease. Upcoming trials will determine if lowering Lp(a) with medication reduces cardiovascular events.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Lipoprotein(a) (Lp(a)) is an LDL-like particle.
  • Elevated Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis.
  • No current trials demonstrate if Lp(a) lowering reduces ASCVD risk alongside optimal LDL cholesterol control.

Purpose of the Study:

  • To summarize ongoing clinical trials investigating targeted Lp(a) lowering pharmacotherapy.
  • To identify large-scale outcome trials assessing cardiovascular endpoints.

Main Methods:

  • Searched ClinicalTrials.gov for relevant studies as of May 2025.
  • Included twelve clinical studies meeting the criteria.
  • Focused on phase 2 and phase 3 trials, including three major phase 3 outcome trials.

Main Results:

  • Three major phase 3 outcome trials (Lp(a)HORIZON, OCEAN(a), ACCLAIM-Lpa(a)) are evaluating pelacarsen, olpasiran, and lepodisiran.
  • These trials assess major adverse cardiac event (MACE) endpoints.
  • Other phase 2 and phase 3 trials are also in progress.

Conclusions:

  • Upcoming trial results are anticipated to clarify the impact of Lp(a) reduction on cardiovascular clinical outcomes.
  • The findings will determine if targeted Lp(a) lowering improves patient prognosis.
Abstract

Keywords:
Cardiovascular disease preventionlipoprotein (a)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.5K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
77